Molecular pathology and genetics of pancreatic endocrine tumours

Journal of Molecular Endocrinology

Volumn 49, Issue 1, 2012, Pages

  Capurso, Gabriele ^a   Festa, Stefano ^a   Valente, Roberto ^a   Piciucchi, Matteo ^a   Panzuto, Francesco ^a   Jensen, Robert T ^b   Fave, Gianfranco Delle ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

CANCER PROGNOSIS; CARCINOGENESIS; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HUMAN; MICROARRAY ANALYSIS; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; ONCOGENE; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

CARCINOMA, NEUROENDOCRINE; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA; ONCOGENE PROTEINS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; VON HIPPEL-LINDAU DISEASE;

EID: 84863505019     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-12-0069     Document Type: Review

References (103)

1. Amato E, Barbi S, Malpeli G, Bersani S, Pelosi G, Capelli P & Scarpa A 2011 Chromosome 3p alterations in pancreatic endocrine neoplasia. Virchows Archiv 458 39-45. (doi:10.1007/s00428-010-1001-x)
2. Averous J & Proud CG 2006 When translation meets transformation: the mTOR story. Oncogene 25 6423-6435. (doi:10.1038/sj.onc. 1209887)
3. Azzoni C, Bottarelli L, Pizzi S, D'Adda T, Rindi G & Bordi C 2006 Xq25 and Xq26 identify the common minimal deletion region in malignant gastroenteropancreatic endocrine carcinomas. Virchows Archiv 448 119-126. (doi:10.1007/s00428-005-0058-4)
4. Barghorn A, Komminoth P, Bachmann D, Rütimann K, Saremaslani P, Muletta-Feurer S, Perren A, Roth J, Heitz PU & Speel EJ 2001 Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression. Journal of Pathology 194 451-458. (doi:10.1002/path.886)
5. Bartsch D, Hahn SA, Danichevski KD, Ramaswamy A, Bastian D, Galehdari H, Barth P, Schmiegel W, Simon B & Rothmund M 1999 Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumours. Oncogene 18 2367-2371. (doi:10.1038/sj.onc.1202585)
6. Bartz C, Ziske C, Wiedenmann B & Moelling K 1996 P53 tumour suppressor gene expression in pancreatic neuroendocrine tumour cells. Gut 38 403-409. (doi:10.1136/gut.38.3.403)
7. Beghelli S, Pelosi G, Zamboni G, Falconi M, Iacono C, Bordi C & Scarpa A 1998 Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p. Journal of Pathology 186 41-50. (doi:10.1002/(SICI)1096-9896(199809)186:1!41::AID-PATH172O3.0.CO;2-L)
8. Bloomston M, Durkin A, Yang I, Rojiani M, Rosemurgy AS, Enkmann S, Yeatman TJ & Zervos EE 2004 Identification of molecular markers specific for pancreatic neuroendocrine tumours by genetic profiling of core biopsies. Annals of Surgical Oncology 11 413-419. (doi:10.1245/ASO.2004.03.077)
9. Capurso G, Lattimore S, Crnogorac-Jurcevic T, Panzuto F, Milione M, Bhakta V, Campanini N, Swift SM, Bordi C, Delle Fave G et al. 2006 Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocrine-Related Cancer 13 541-558. (doi:10.1677/erc.1.01153)
10. Chen YJ, Vortmeyer A, Zhuang Z, Huang S & Jensen RT 2003 Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance. Cancer Research 63 817-823.
11. Chen YJ, Vortmeyer A, Zhuang Z, Gibril F & Jensen RT 2004 X-chromosome, loss of heterozygosity frequently occurs in gastrinomas and is correlated with aggressive tumour growth. Cancer 100 1379-1387. (doi:10.1002/cncr.20104)
12. Chetty R, Serra S & Asa SL 2008 Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors. American Journal of Surgical Pathology 32 413-419.
13. Chung DC, Smith AP, Louis DN, Graeme-Cook F, Warshaw AL & Arnold A 1997 Analysis of the retinoblastoma tumour suppressor gene in pancreatic endocrine tumours. Clinical Endocrinology 47 423-428. (doi:10.1046/j.1365-2265.1997.2861110.x)
14. Chung DC, Brown SB, Graeme-Cook F, Tillotson LG, Warshaw AL, Jensen RT & Arnold A 1998 Localization of putative tumour suppressor loci by genomewide allelotyping in human pancreatic endocrine tumours. Cancer Research 58 3706-3711.
15. Chung DC, Brown SB, Graeme-Cook F, Seto M, Warshaw AL, Jensen RT & Arnold A 2000 Overexpression of cyclin D1 in sporadic pancreatic endocrine tumours. Journal of Clinical Endocrinology and Metabolism 85 4373-4378. (doi:10.1210/jc.85.11.4373)
16. Corbo V, Dalai I, Scardoni M, Barbi S, Beghelli S, Bersani S, Albarello L, Doglioni C, Schott C, Capelli P et al. 2010 MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocrine-Related Cancer 17 771-783. (doi:10.1677/ERC-10-0028)
17. Corbo V, Beghelli S, Bersani S, Antonello D, Talamini G, Brunelli M, Capelli P, Falconi M & Scarpa A 2012 Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. Annals of Oncology 23 127-134. (doi:10.1093/ annonc/mdr048)
18. Corcos O, Couvelard A, Giraud S, Vullierme MP, O'Toole D, Rebours V, Stievenart JL, Penfornis A, Niccoli-Sire P, Baudin E et al. 2008 Endocrine pancreatic tumours in von Hippel-Lindau disease: clinical, histological, and genetic features. Pancreas 37 85-93. (doi:10.1097/MPA.0b013e31815f394a)
19. Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K et al. 2005 Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. British Journal of Cancer 92 94-101. (doi:10.1038/sj.bjc.6602245)
20. Couvelard A, Hu J, Steers G, O'Toole D, Sauvanet A, Belghiti J, Bedossa P, Gatter K, Ruszniewski P & Pezzella F 2006 Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumours. Gastroenterology 131 1597-1610. (doi:10.1053/j.gastro.2006.09.007)
21. Curatolo P, Bombardieri R & Jozwiak S 2008 Tuberous sclerosis. Lancet 372 657-668. (doi:10.1016/S0140-6736(08)61279-9)
22. Dammann R, Schagdarsurengin U, Liu L, Otto N, Gimm O, Dralle H, Boehm BO, Pfeifer GP & Hoang-Vu C 2003 Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 22 3806-3812. (doi:10.1038/sj.onc.1206582)
23. Di Florio A, Capurso G, Milione M, Panzuto F, Geremia R, Delle Fave G & Sette C 2007 Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells. Endocrine-Related Cancer 14 111-124. (doi:10.1677/erc.1.01318)
24. Di Florio A, Adesso L, Pedrotti S, Capurso G, Pilozzi E, Corbo V, Scarpa A, Geremia R, Delle Fave G & Sette C 2011 Src kinase activity coordinates cell adhesion and spreading with activation of mTOR in pancreatic endocrine tumor cells. Endocrine-Related Cancer 18 541-554. (doi:10.1530/ERC-10-0153)
25. Dilley WG, Kalyanaraman S, Verma S, Cobb JP, Laramie JM & Lairmore TC 2005 Global gene expression in neuroendocrine tumours from patients with MEN-I syndrome. Molecular Cancer 4 9.(doi:10.1186/1476-4598-4-9)
26. Ding L, Wendl MC, Koboldt DC & Mardis ER 2010 Analysis of nextgeneration genomic data in cancer: accomplishments and challenges. Human Molecular Genetics 19 R188-R961. (doi:10.1093/ hmg/ddq391)
27. Duerr EM, Mizukami Y, Ng A, Xavier RJ, Kikuchi H, Deshpande V, Warshaw AL, Glickman J, Kulke MH & Chung DC 2008 Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumours through DNA microarray analysis. Endocrine-Related Cancer 15 243-256. (doi:10.1677/ERC-07-0194)
28. Ebrahimi SA, Wang EH, Wu A, Schreck RR, Passaro E Jr & Sawicki MP 1999 Deletion of chromosome 1 predicts prognosis in pancreatic endocrine tumours. Cancer Research 59 311-315.
29. Evers BM, Rady PL, Sandoval K, Arany I, Tyring SK, Sanchez RL, Nealon WH, Townsend CM Jr & Thompson JC 1994 Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene. Annals of Surgery 219 596-601 (discussion 602-604). (doi:10.1097/ 00000658-199406000-00002)
30. Fitzgerald TL, Hickner ZJ, Schmitz M & Kort EJ 2008 Changing incidence of pancreatic neoplasms. A 16-year review of statewide tumor registry. Pancreas 37 134-138. (doi:10.1097/MPA. 0b013e318163a329)
31. Fjallskog ML, Lejonklou MH, Oberg KE, Eriksson BK & Jansonn ET 2003 Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumours. Clinical Cancer Research 9 1469-1473.
32. Floridia G, Grilli G, Salvatore M, Pescucci C, Moore PS, Scarpa A & Taruscio D 2005 Chromosomal alterations detected by comparative genomic hybridization in nonfunctioning endocrine pancreatic tumours. Cancer Genetics and Cytogenetics 156 23-30. (doi:10.1016/ j.cancergencyto.2004.04.015)
33. Furukawa M, Raffeld M, Mateo C, Sakamoto A, Moody TW, Ito T, Venzon DJ, Serrano J & Jensen RT 2005 Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clinical Cancer Research 11 3233-3242. (doi:10.1158/ 1078-0432.CCR-04-1915)
34. Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P et al. 2011 Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology 141 1728-1737. (doi:10.1053/j.gastro.2011. 07.037)
35. Goebel SU, Heppner C, Burns AL, Marx SJ, Spiegel AM, Zhuang Z, Lubensky IA, Gibril F, Jensen RT & Serrano J 2000 Genotype/ phenotype correlation of multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas. Journal of Clinical Endocrinology and Metabolism 85 116-123. (doi:10.1210/jc.85.1.116)
36. Goebel SU, Iwamoto M, Raffeld M, Gibril F, Hou W, Serrano J & Jensen RT 2002 Her-2/neu expression and gene amplification in gastrinomas: correlations with tumour biology, growth, and aggressiveness. Cancer Research 62 3702-3710.
37. Görtz B, Roth J, Krähenmann A, de Krijger RR, Muletta-Feurer S, Rütimann K, Saremaslani P, Speel EJ, Heitz PU & Komminoth P 1999 Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. American Journal of Pathology 154 429-436. (doi:10.1016/S0002-9440(10)65289-3)
38. Guo SS, Wu AY & Sawicki MP 2002a Deletion of chromosome 1, but not mutation of MEN-1, predicts prognosis in sporadic pancreatic endocrine tumours. World Journal of Surgery 26 843-847. (doi:10.1007/s00268-002-4062-4)
39. Guo SS, Arora C, Shimoide AT & Sawicki MP 2002b Frequent deletion of chromosome 3 in malignant sporadic pancreatic endocrine tumours. Molecular and Cellular Endocrinology 190 109-114. (doi:10.1016/S0303-7207(02)00002-3)
40. Guo SS, Wu X, Shimoide AT, Wong J, Moatamed F & Sawicki MP 2003 Frequent overexpression of cyclin D1 in sporadic pancreatic endocrine tumours. Journal of Endocrinology 179 73-79. (doi:10.1677/joe.0.1790073)
41. Hanahan D & Folkman J 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 353-364. (doi:10.1016/S0092-8674(00)80108-7)
42. Hansel DE, Rahman A, House M, Ashfaq R, Berg K, Yeo CJ & Maitra A 2004 Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in welldifferentiated pancreatic endocrine neoplasms. Clinical Cancer Research 10 6152-6158. (doi:10.1158/1078-0432.CCR-04-0285)
43. Harvey M, Vogel H, Lee EY, Bradley A & Donehower LA 1995 Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Research 55 1146-1151.
44. Hervieu V, Lepinasse F, Gouysse G, Guillaud O, Barel C, Chambonniere ML, Bringuier PP, Poncet G, Lombard-Bohas C, Partensky C et al. 2006 Expression of beta-catenin in gastroenteropancreatic endocrine tumours: a study of 229 cases. Journal of Clinical Pathology 59 1300-1304. (doi:10.1136/jcp.2005.035097)
45. Hu W, Feng Z, Modica I, Klimstra DS, Song L, Allen PJ, Brennan MF, Levine AJ & Tang LH 2010 Gene amplifications in welldifferentiated pancreatic neuroendocrine tumors inactivate the p53 pathway. Genes & Cancer 4 360-368. (doi:10.1177/ 1947601910371979)
46. Huang J, Gurung B, Wan B, Matkar S, Veniaminova NA, Wan K, Merchant JL, Hua X & Lei M 2012 The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 482 542-546. (doi:10.1038/nature10806)
47. Jensen RT & Delle Fave G 2011 Promising advances in the treatment of malignant pancreatic endocrine tumors. New England Journal of Medicine 364 564-565. (doi:10.1056/NEJMe 1013903)
48. Jensen RT, Berna MJ, Bingham DB & Norton JA 2008 Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 113 (Suppl 7) 1807-1843. (doi:10.1002/cncr.23648)
49. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA et al. 2011 DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331 1199-1203. (doi:10.1126/ science.1200609)
50. Jonkers YM, Claessen SM, Perren A, Schmid S, Komminoth P, Verhofstad AA, Hofland LJ, de Krijger RR, Slootweg PJ, Ramaekers FC et al. 2005 Chromosomal instability predicts metastatic disease in patients with insulinomas. Endocrine-Related Cancer 12 435-447. (doi:10.1677/erc.1.00960)
51. Jonkers YM, Claessen SM, Feuth T, van Kessel AG, Ramaekers FC, Veltman JA & Speel EJ 2006 Novel candidate tumour suppressor gene loci on chromosomes 11q23-24 and 22q13 involved in human insulinoma tumourigenesis. Journal of Pathology 210 450-458. (doi:10.1002/path.2072)
52. Karnik SK, Hughes CM, Gu X, Rozenblatt-Rosen O, McLean GW, Xiong Y, Meyerson M & Kim SK 2005 Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. PNAS 102 14659-14664. (doi:10.1073/pnas.0503484102)
53. Kasajima A, Pavel M, Darb-Esfahani S, Noske A, Stenzinger A, Sasano H, Dietel M, Denkert C, Röcken C, Wiedenmann B et al. 2011 mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer 18 181-192. (doi:10.1677/ERC-10-0126)
54. Koch CA, Gimm O, Vortmeyer AO, Al-Ali HK, Lamesch P, Ott R, Kluge R, Bierbach U & Tannapfel A 2006 Does the expression of c-kit (CD117) in neuroendocrine tumours represent a target for therapy? Annals of the New York Academy of Sciences 1073 517-526. (doi:10.1196/annals.1353.055)
55. Lemos MC & Thakker RV 2008 Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Human Mutation 29 22-32. (doi:10.1002/humu.20605)
56. Lott ST, Chandler DS, Curley SA, Foster CJ, El-Naggar A, Frazier M, Strong LC, Lovell M & Killary AM 2002 High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumours: evidence for a stepwise mechanism for malignant conversion in VHL tumourigenesis. Cancer Research 62 1952-1955.
57. Maitra A, Hansel DE, Argani P, Ashfaq R, Rahman A, Naji A, Deng S, Geradts J, Hawthorne L, House MG et al. 2003 Global expression analysis of well differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clinical Cancer Research 95 988-995.
58. McClatchey AI 2007 Neurofibromatosis. Annual Review of Pathology 2 191-216. (doi:10.1146/annurev.pathol.2.010506.091940)
59. Metz DC & Jensen RT 2008 Gastrointestinal neuroendocrine tumours: pancreatic endocrine tumours. Gastroenterology 135 1469-1492. (doi:10.1053/j.gastro.2008.05.047)
60. Missiaglia E, Moore PS, Williamson J, Lemoine NR, Falconi M, Zamboni G & Scarpa A 2002 Sex chromosome anomalies in pancreatic endocrine tumours. International Journal of Cancer 98 532-538. (doi:10.1002/ijc.10223)
61. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G et al. 2010 Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. Journal of Clinical Oncology 28 245-255. (doi:10.1200/JCO.2008.21.5988)
62. Moore PS, Missiaglia E, Antonello D, Zamo A, Zamboni G, Corleto V, Falconi M & Scarpa A 2001a Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL. Genes, Chromosomes & Cancer 32 177-181. (doi:10.1002/gcc.1180)
63. Moore PS, Orlandini S, Zamboni G, Capelli P, Rigaud G, Falconi M, Bassi C, Lemoine NR & Scarpa A 2001b Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but in exocrine nonductal or endocrine tumourigenesis. British Journal of Cancer 84 253-262. (doi:10.1054/bjoc.2000.1567)
64. Mukhopadhyay B, Sahdev A, Monson JP, Besser GM, Reznek RH & Chew SL 2002 Pancreatic lesions in von Hippel-Lindau disease. Clinical Endocrinology 57 603-608. (doi:10.1046/j.1365-2265.2002. 01637.x)
65. Nagano Y, Kim do H, Zhang L, White JA, Yao JC, Hamilton SR & Rashid A 2007 Allelic alterations in pancreatic endocrine tumours identified by genomewide single nucleotide polymorphism analysis. Endocrine-Related Cancer 14 483-492. (doi:10.1677/ERC-06-0090)
66. Nikiforova MN, Nikiforov YE, Biddinger P, Gnepp DR, Grosembacher LA, Wajchenberg BL, Fagin JA & Cohen RM 1999 Frequent loss of heterozygosity at chromosome 3p14.2-3p21 in human pancreatic islet cell tumours. Clinical Endocrinology 51 27-33. (doi:10.1046/j.1365-2265. 1999.00785.x)
67. Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G, Scarpa A, De Braud F, Dogliotti L, Tomassetti P et al. 2011 Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. Journal of Clinical Oncology 29 2372-2377. (doi:10.1200/JCO.2010.33.0688)
68. Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM & Lloyd RV 2005 Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Modern Pathology 18 1329-1335. (doi:10.1038/modpathol. 3800427)
69. Pavelic K, Hrascan R, Kapitanovic S, Vranes Z, Cabrijan T, Spaventi S, Korsic M, Krizanac S, Li YQ, Stambrook P et al. 1996 Molecular genetics of malignant insulinoma. Anticancer Research 16 1707-1717.
70. Peghini PL, Iwamoto M, Raffeld M, Chen YJ, Goebel SU, Serrano J & Jensen RT 2002 Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clinical Cancer Research 8 2273-2285.
71. Périgny M, Hammel P, Corcos O, Larochelle O, Giraud S, Richard S, Sauvanet A, Belghiti J, Ruszniewski P, Bedossa P et al. 2009 Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression. American Journal of Surgical Pathology 33 739-748. (doi:10.1097/PAS.0b013e3181967992)
72. Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, Heitz PU & Eng C 2000 Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. American Journal of Pathology 157 1097-1103. (doi:10.1016/S0002-9440(10)64624-X)
73. Perren A, Anlauf M, Henopp T, Rudolph T, Schmitt A, Raffel A, Gimm O, Weihe E, Knoefel WT, Dralle H et al. 2007 Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. Journal of Clinical Endocrinology and Metabolism 92 1118-1128. (doi:10.1210/jc.2006-1944)
74. Pizzi S, D'Adda T, Azzoni C, Rindi G, Grigolato P, Pasquali C, Corleto VD, Delle Fave G & Bordi C 2002 Malignancy-associated allelic losses on the X-chromosome in foregut but not in midgut endocrine tumours. Journal of Pathology 196 401-407. (doi:10.1002/path.1075)
75. Pizzi S, Azzoni C, Bottarelli L, Campanini N, D'Adda T, Pasquali C, Rossi G, Rindi G & Bordi C 2005 RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours. Journal of Pathology 206 409-416. (doi:10.1002/path.1784)
76. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A et al. 2011 Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine 364 501-513. (doi:10.1056/NEJMoa1003825)
77. Rigaud G, Missiaglia E, Moore PS, Zamboni G, Falconi M, Talamini G, Pesci A, Baron A, Lissandrini D, Rindi G et al. 2001 High resolution allelotype of nonfunctional pancreatic endocrine tumours: identification of two molecular subgroups with clinical implications. Cancer Research 61 285-292.
78. Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A et al. 2006 MicroRNA expression abnormalities in pancreatic endocrine and acinar tumours are associated with distinctive pathologic features and clinical behaviour. Journal of Clinical Oncology 24 4677-4684. (doi:10.1200/JCO.2005.05.5194)
79. Roncalli M, Springall DR, Varndell IM, Gaitonde VV, Hamid Q, Ibrahim NB, Grimelius L, Wilander E, Polak JM, Coggi G et al. 1991 Oncoprotein immunoreactivity in human endocrine tumours. Journal of Pathology 63 117-127. (doi:10.1002/path.1711630207)
80. Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C & HengstschlägerM 2008a The mTOR pathway and its role in human genetic diseases. Mutation Research 659 284-292. (doi:10.1016/j.mrrev. 2008.06.001)
81. Rosner M, Hanneder M, Siegel N, Valli A & Hengstschläger M 2008b The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutation Research 658 234-246. (doi:10.1016/j.mrrev. 2008.01.001)
82. Rubbia-Brandt L, Terris B, Giostra E, Dousset B, Morel P & Pepper MS 2004 Lymphatic vessel density and vascular endothelial growth factor-C expression correlate with malignant behavior in human pancreatic endocrine tumors. Clinical Cancer Research 10 6919-6928. (doi:10.1158/1078-0432.CCR-04-0397)
83. Schmitt AM, Schmid S, Rudolph T, Anlauf M, Prinz C, Klöppel G, Moch H, Heitz PU, Komminoth P & Perren A 2009 VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocrine-Related Cancer 16 1219-1227. (doi:10.1677/ERC-08-0297)
84. Serrano J, Goebel SU, Peghini PL, Lubensky IA, Gibril F & Jensen RT 2000 Alterations in the p16 INK4a/CDKN2A tumour suppressor gene in gastrinomas. Journal of Clinical Endocrinology and Metabolism 85 4146-4156. (doi:10.1210/jc.85.11.4146)
85. Shida T, Kishimoto T, Furuya M, Nikaido T, Koda K, Takano S, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M et al. 2010 Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemotherapy and Pharmacology 65 889-893. (doi:10.1007/s00280-009-1094-6)
86. Speel EJ, Richter J, Moch H, Egenter C, Saremaslani P, Rütimann K, Zhao J, Barghorn A, Roth J, Heitz PU et al. 1999 Genetic differences in endocrine pancreatic tumour subtypes detected by comparative genomic hybridization. American Journal of Pathology 155 1787-1794. (doi:10.1016/S0002-9440(10)65495-8)
87. Speel EJ, Scheidweiler AF, Zhao J, Matter C, Saremaslani P, Roth J, Heitz PU & Komminoth P 2001 Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumours: gain of 9Q34 is an early event in insulinomas. Cancer Research 61 5186-5192.
88. Srivastava A, Alexander J, Lomakin I & Dayal Y 2001 Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in pancreatic endocrine tumours. Human Pathology 32 1184-1189. (doi:10.1053/hupa.2001.28959)
89. Stumpf E, Aalto Y, Hoog A, Kjellman M, Otonkoski T, Knuutila S & Andersson LC 2000 Chromosomal alterations in human pancreatic endocrine tumours. Genes, Chromosomes & Cancer 29 83-87. (doi:10. 1002/1098-2264(2000)9999:9999!::AID-GCC1011O3.0.CO;2-Z)
90. Tannapfel A, Vomschloss S, Karhoff D, Markwarth A, Hengge UR, Wittekind C, Arnold R & Hörsch D 2005 BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumours. American Journal of Clinical Pathology 123 256-260. (doi:10.1309/ YQBR9C05RU4DD3RN)
91. Terris B, Meddeb M, Marchio A, Danglot G, Fléjou JF, Belghiti J, Ruszniewski P & Bernheim A 1998 Comparative genomic hybridization analysis of sporadic neuroendocrine tumours of the digestive system. Genes, Chromosomes & Cancer 22 50-56. (doi:10.1002/(SICI)1098-2264(199805)22:1!50::AID-GCC7O3.0. CO;2-6)
92. Tonnies H, Toliat MR, Ramel C, Pape UF, Neitzel H, Berger W & Wiedenmann B 2001 Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridization. Gut 48 536-541. (doi:10.1136/gut.48.4.536)
93. Walter T, Brixi-Benmansour H, Lombard-Bohas C & Cadiot J 2012 New treatment strategies in advanced neuroendocrine tumours. Digestive and Liver Disease 44 95-105. (doi:10.1016/j.dld.2011.08.022)
94. Wang DG, Johnston CF, Anderson N, Sloan JM & Buchanan KD 1995 Overexpression of the tumour suppressor p53 is not implicated in neuroendocrine tumour carcinogenesis. Journal of Pathology 175 397-401. (doi:10.1002/path.1711750406)
95. Wang DG, Johnston CF & Buchanan KD 1997 Oncogene expression in gastroenteropancreatic neuroendocrine tumours: implications for pathogenesis. Cancer 80 668-675. (doi:10.1002/(SICI)1097-0142(19970815)80:4!668::AID-CNCR4O3.0.CO;2-J)
96. Wang Y, Ozawa A, Zaman S, Prasad NB, Chandrasekharappa SC, Agarwal SK & Marx SJ 2011 The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization. Cancer Research 71 371-382. (doi:10.1158/0008-5472.CAN-10-3221)
97. Wild A, Langer P, Ramaswamy A, Chaloupka B & Bartsch DK 2001 A novel insulinoma tumour suppressor gene locus on chromosome 22q with potential prognostic implications. Journal of Clinical Endocrinology and Metabolism 86 5782-5787. (doi:10.1210/jc.86.12. 5782)
98. Wild A, Langer P, Celik I, Chaloupka B & Bartsch DK 2002 Chromosome 22q in pancreatic endocrine tumours: identification of a homozygous deletion and potential prognostic associations of allelic deletions. European Journal of Endocrinology 147 507-513. (doi:10.1530/eje.0.1470507)
99. Yang YM, Liu TH, Chen YJ, Jiang WJ, Qian JM, Lu X, Gao J, Wu SF, Sang XT & Chen J 2005 Chromosome 1q loss of heterozygosity frequently occurs in sporadic insulinomas and is associated with tumour malignancy. International Journal of Cancer 117 234-240. (doi:10.1002/ijc.21175)
100. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG et al. 2011 RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 364 514-523. (doi:10.1056/ NEJMoa1009290)
101. Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey JN, Xie K & Yao JC 2007 Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109 1478-1486. (doi:10.1002/cncr. 22554)
102. Zhang L, Smyrk TC, Oliveira AM, Lohse CM, Zhang S, Johnson MR & Lloyd RV 2009 KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers. American Journal of Surgical Pathology 33 1562-1569. (doi:10.1097/PAS.0b013e3181ac675b)
103. Zhao J, Moch H, Scheidweiler AF, Baer A, Schäffer AA, Speel EJ, Roth J, Heitz PU & Komminoth P 2001 Genomic imbalances in the progression of endocrine pancreatic tumours. Genes, Chromosomes& Cancer 32 364-372. (doi:10.1002/gcc.1201)